TITLE

SERONO'S GONAL-F APPROVED IN JAPAN FOR HYPOGONADISM

PUB. DATE
March 2006
SOURCE
Worldwide Biotech;Mar2006, Vol. 18 Issue 3, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the approval given by the Japanese Ministry of Health, Labour and Welfare on the follitropin alfa recombinant subcutaneous injection developed by Serono. Use of the drug for the induction of spermatogenesis in men with hypogonadotropic hypogonadism; Remarks from company executive Jacques Theurillat regarding the approval; Corporate background of the company.
ACCESSION #
20451868

 

Related Articles

  • Omega 3 Prescription Drug Approved in Japan.  // Nutraceuticals World;Nov2012, Vol. 15 Issue 9, p10 

    The article reports that the Japanese Ministry of Health, Labour and Welfare has apposed a New Drug Application (NDA) for Pronova BioPharma ASA and Takeda Pharmaceutical Co. Ltd.'s Lotigo granular capsule for the treatment of hyperlipidemia.

  • Cyberonics' VNS gets Japanese regulatory approval for epilepsy.  // Medical Device Daily;1/22/2010, Vol. 14 Issue 14, p1 

    The article deals with the final regulatory approval granted by the Japanese Ministry of Health, Labor & Welfare to Cyberonics in January 2010 to market and sell its vagus nerve stimulation (VNS) therapy system for the epilepsy indication. The business opportunity in Japan is described by...

  • Mochida Pharmaceutical obtains Japanese approval for depression drug.  // PharmaWatch: CNS;Jun2011, Vol. 10 Issue 6, p23 

    The article reports on the approval obtained by Mochida Pharmaceutical Co., Ltd., a business partner of H. Lundbeck A/S, from the Japanese Ministry of Health, Labour and Welfare for its Lexapro 10 milligrams (mg) or escitalopram, which is used to treat people suffering from depression.

  • Sanofi-Aventis wins Japanese approval for Taxotere to treat prostate cancer.  // PharmaWatch: Cancer;Oct2008, Vol. 7 Issue 10, p15 

    The article reports on the approval granted by the Japanese Ministry of Health, Labor and Welfare to Sanofi-Aventis SA for use of Taxotere injection in prostate cancer. It is noted that Taxotere has been approved in Japan for the treatment of several diseases including breast cancer, non-small...

  • Celgene: Revlimid set to break into Japan's multiple myeloma market.  // PharmaWatch: Cancer;Aug2009, Vol. 8 Issue 8, p11 

    The article reports on the submission of a New Drug Application (NDA) by biopharmaceutical company Celgene Corp. for Revlimid with dexamethasone therapeutic for multiple myeloma to the Ministry of Health, Labor and Welfare in Japan. The filing of NDA has been taken after the presentation of the...

  • Novartis receives Japanese approval for Gilenya and Illaris.  // PharmaWatch: CNS;Nov2011, Vol. 10 Issue 11, p4 

    The article reports on the approval received by Novartis International AG from the Ministry of Health, Labor and Welfare of Japan for the drugs Gilenya to prevent the relapse and delay of progression of physical disability in adults with multiple sclerosis (MS), and for Illaris to...

  • Celgene: Revlimid set to break into Japan's multiple myeloma market.  // PharmaWatch: Monthly Review;Aug2009, Vol. 8 Issue 8, p8 

    In this article, the author discusses the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labor and Welfare by Celgene Corp. for Revlimid in combination with dexamethasone for treatment of patients with multiple myeloma. The author notes that the submission of NDA comes...

  • Abraxis partner Taiho files Abraxane NDA in Japan.  // PharmaWatch: Biotechnology;May2008, Vol. 7 Issue 5, p9 

    The article reports on the new drug application filed by Taiho Pharmaceuticals Co., the partner of Abraxis BioScience, with the Ministry of Health, Labor and Welfare in Japan. The application seeks to market Abraxane for injectable suspension to treat breast cancer. It includes several...

  • CNS News Round-Up.  // PharmaWatch: CNS;Sep2011, Vol. 10 Issue 9, p2 

    The article offers pharmaceutical news briefs. It says that Biogen Idec received conditional approval from European Union for Fampyra drug which improves the walking of adult patients with multiple sclerosis (MS). It states that Dainippon Sumitomo Pharma (DSP) received the approval for...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics